BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35604010)

  • 1. Editorial for "Comparing Survival Outcomes of Patients With LI-RADS-M Hepatocellular Carcinomas and Intrahepatic Cholangiocarcinomas".
    Yoon JH
    J Magn Reson Imaging; 2023 Jan; 57(1):318-319. PubMed ID: 35604010
    [No Abstract]   [Full Text] [Related]  

  • 2. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 3. MRI appearance of combined hepatocellular cholangiocarcinoma.
    Billet N; Grégory J; Ronot M
    Diagn Interv Imaging; 2022 Dec; 103(12):625-626. PubMed ID: 36243674
    [No Abstract]   [Full Text] [Related]  

  • 4. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 5. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.
    Chen LD; Ruan SM; Liang JY; Yang Z; Shen SL; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    World J Gastroenterol; 2018 Sep; 24(33):3786-3798. PubMed ID: 30197484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Wang LF; Guan X; Shen YT; Zhou BY; Sun YK; Li XL; Yin HH; Lu D; Ye X; Hu XY; Yang DH; Xia HS; Wang X; Lu Q; Han H; Xu HX; Zhao CK;
    Abdom Radiol (NY); 2024 Feb; 49(2):458-470. PubMed ID: 38225379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial for "LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study".
    Liu X; Shan Q; Wang Z
    J Magn Reson Imaging; 2023 Mar; 57(3):939-940. PubMed ID: 35986651
    [No Abstract]   [Full Text] [Related]  

  • 9. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI.
    Choi SH; Jeon SK; Lee SS; Lee JM; Hur BY; Kang HJ; Kim H; Park Y
    Eur Radiol; 2021 Dec; 31(12):9479-9488. PubMed ID: 34037829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
    Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
    Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality imaging of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Shahbazian H; Mirza-Aghazadeh-Attari M; Borhani A; Mohseni A; Madani SP; Ansari G; Pawlik TM; Kamel IR
    J Surg Oncol; 2023 Sep; 128(4):519-530. PubMed ID: 37439096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.
    Kim SS; Lee S; Choi JY; Lim JS; Park MS; Kim MJ
    Abdom Radiol (NY); 2020 Nov; 45(11):3743-3754. PubMed ID: 32377757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Guo HL; Zheng X; Cheng MQ; Zeng D; Huang H; Xie XY; Lu MD; Kuang M; Wang W; Xian MF; Chen LD
    J Ultrasound Med; 2022 May; 41(5):1213-1225. PubMed ID: 34423864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.
    Zheng W; Huang H; She D; Xiong M; Chen X; Lin X; Cao D
    Abdom Radiol (NY); 2022 Mar; 47(3):957-968. PubMed ID: 34964069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.
    Li F; Li Q; Liu Y; Han J; Zheng W; Huang Y; Zheng X; Cao L; Zhou JH
    Eur Radiol; 2020 Jan; 30(1):461-470. PubMed ID: 31297632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Survival Outcomes of Patients With LI-RADS-M Hepatocellular Carcinomas and Intrahepatic Cholangiocarcinomas.
    Kierans AS; Lafata KJ; Ludwig DR; Burke LMB; Chernyak V; Fowler KJ; Fraum TJ; McGinty KA; McInnes MDF; Mendiratta-Lala M; Cunha GM; Allen BC; Hecht EM; Jaffe TA; Kalisz KR; Ranathunga DS; Wildman-Tobriner B; Cardona DM; Aslam A; Gaur S; Bashir MR
    J Magn Reson Imaging; 2023 Jan; 57(1):308-317. PubMed ID: 35512243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.